

14 ~~13~~ The cell line of claim ~~9~~¹⁰ that is a eucaryotic cell line.

15 ~~14~~ The cell line of claim ~~9~~¹⁰ that is a procaryotic cell line.

16 ~~15~~ A method of making the antibody of claim ~~2~~³ comprising:

- (a) immunizing an animal with the polypeptide of claim ~~2~~³ under conditions to elicit an antibody response;
- (b) isolating antibody-producing cells from the animal;
- (c) fusing the antibody-producing cells with immortalized cells in culture to form monoclonal antibody-producing hybridoma cells;
- (d) culturing the hybridoma cells; and
- (e) isolating from the culture monoclonal antibodies which specifically bind to the polypeptide of claim ~~2~~³.

17 ~~16~~ A composition comprising an antibody according to claim ~~2~~³, and a pharmaceutically acceptable carrier.

REMARKS

STATUS OF THE CLAIMS

Original claim 1 was canceled. New claims 1-16 will be pending after entry of this amendment. Support for new claims 1-16 can be found throughout the specification and in the claims as originally filed (and issued in related and corresponding U.S. Patent No. 6,132,987). The claims are generally related to antibodies of the novel chemokine receptors, MCP-1RA and MCP-1RB. These receptors are alternatively spliced versions of MCP-1 receptor protein.

Support for the generation and production of antibodies is well known to one of skill in the art and can be found throughout the instant application. Specifically, support can be found, for example, at page 7, line 15 through page 8, line 3, in the numerous references cited and which have been incorporated by reference for all

Israel F. Charo
Application No.: 09/625,573
Page 5


PATENT

purposes. Additional support for incorporation by reference can be found at page 46, lines 21-24.

Applicants request that the application now be examined on the merits.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned attorney at 650-326-2400 x 5228.

Respectfully submitted,


Andrew T. Serafini, Ph.D.
Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
ATS:ksj

PA 3225365 v1